Navigation Links
Secrets of lung cancer drug resistance revealed at UCSF

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will returnit's a question of when. And for far too many, it happens far too soon.

Now, a team of researchers at the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center has discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug.

The discovery, described this week in Nature Genetics, may lead to better treatments involving precision medicines that would combine Tarceva with new drugs designed to block AXL.

"If we block AXL activation in the laboratory, we can overcome resistance to Tarceva," said Trever Bivona, MD, PhD, an assistant professor of hematology and oncology. "This paves the way for novel and more effective therapies."

In the experiments, Bivona and his colleagues used an inhibitor of AXL that is not an ideal clinical drug. But now Bivona and his team are working together with Kevan Shokat, PhD, a Howard Hughes Medical Institute Investigator and chair of the UCSF Department of Cellular and Molecular Pharmacology, to develop more potent AXL inhibitors for clinical testing.

Lung Cancer is Number One Cancer Killer

Lung cancer is the most common cause of cancer death worldwide. More people die from the disease each year than from breast, colon and prostate cancers combined. It claims more than 150,000 American lives annually and accounts for some 1.4 million deaths around the world. About 85 percent of Americans with all types of lung cancer die within five years of diagnosis.

Most cases result from exposure to cigarette smoke, but other causes include exposure to asbestos, chemicals, environmental factors and genetic susceptibility.

One thing that makes lung cancer so difficult is that it often goes undetected in its early stages because it usually does not cause symptoms. Only about 30 percent of patients in the United States are detected in the earliest stage of the disease, contributing to its low overall survival rate.

Even people who have their cancer detected at the earliest stages, however, face serious odds. Unlike other types of cancer, where early diagnosis has significant survival advantages, some 35 to 45 percent of people with stage I lung cancer die within five years of recurrent disease.

Though treatment varies depending on the type of lung cancer, its stage, and whether it not it has metastasized to regional lymph nodes, standard treatments usually involve surgery or some combination of surgery, radiation therapy and chemotherapy.

Tarceva is one such chemotherapy drug. Also known as erlotinib, the drug is a targeted therapy that works by blocking an enzyme known as epidermal growth factor receptor (EGFR). Bivona and his colleagues discovered that AXL drives resistance to Tarceva by "rescuing" lung cancers from EGFR inhibitor treatment.

AXL, said Bivona, is the sort of molecule known as a kinase, which makes it a valuable target for drug design. Many of the existing targeted cancer drugs on the market, including Tarceva, work by blocking kinases in one form or another.


Contact: Jason Socrates Bardi
University of California - San Francisco

Related medicine news :

1. Dotcomsecrets is Offering New Opportunities to People Who Want to Become Expert in Localized Internet Marketing
2. DotComSecrets Invites Professionals to Learn Great Tips On How to Make a Handsome Income By Working As Local Internet Marketing Consultants
3. 13 Free Weight Loss Secrets Program Kicks-Off
4. DotComSecrets Offers Free Webinar to Make Individuals Skilled in Earning Thousands of Dollars by Becoming DCS’s Local Consultant
5. DotComSecrets’ Russell Brunson Is Revealing Online Money Making Secrets in Free Webinars for Students
6. DotComSecrets Is Seeking Local DCS Consultants Through Free Webinars in Coming Days
7. Study Suggests Vaccine May Help Kids With Brain Cancer
8. New Stool Test Might Aid in Early Detection of Colon Cancer
9. Study reveals how cancer drug causes diabetic-like state
10. How a cancer drug leads to diabetes
11. You Survived Cancer: Now Pay Attention to Your Overall Health
Post Your Comments:
Related Image:
Secrets of lung cancer drug resistance revealed at UCSF
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: